Daniel Lee

Daniel Lee

Corporate Officer/Principal at
Society For Biomaterials

Net worth: 27 356 $ as of 31/10/2025

65 year
Health Technology
Consumer Services
Commercial Services

Profile

Daniel R.
Lee
is currently a Member at the American Association of Tissue Banks and a Member at the Society For Biomaterials.
Former positions include Chief Executive Officer at Aperion Biologics, Inc. from 2008 to 2015; Chief Executive Officer & Director at Scaffold Biologics, Inc.; Chief Executive Officer & Director at Tissue Regenix Group Plc from 2020 to 2025; Chief Executive Officer at CellRight Technologies LLC from 2019 to 2025; Director-Research & Development at United States Surgical Corp.; Director-Marketing at Regeneration Technologies, Inc.; Marketing Director at OsteoBiologics, Inc. from 2003 to 2006; and Marketing Director at Smith & Nephew Endoscopy, Inc. from 2006 to 2008.
Education includes undergraduate studies at The Johns Hopkins University and graduate studies at The University of Alabama.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
31/12/2024 282,512 ( 0.4% ) 27 356 $ 31/10/2025

Daniel Lee active positions

CompaniesPositionStart
Corporate Officer/Principal -
Corporate Officer/Principal -

Former positions of Daniel Lee

CompaniesPositionEnd
Chief Executive Officer 21/10/2025
TISSUE REGENIX GROUP PLC Chief Executive Officer 16/10/2025
Sales & Marketing 01/08/2008
Sales & Marketing 01/07/2006
Scaffold Biologics, Inc.
Chief Executive Officer -
See the detail of Daniel Lee's experience

Training of Daniel Lee

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

23

1st degree connections

12

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies12

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Commercial Services

Health Technology

Commercial Services

Distribution Services

Distribution Services

Scaffold Biologics, Inc.